Torrent Pharmaceuticals enters into patent licensing agreement with Takeda

05 Jun 2024 Evaluate

Torrent Pharmaceuticals has entered into a non-exclusive patent licensing agreement with Takeda Pharmaceuticals (Takeda) to commercialize Vonoprazan in India. Vonoprozan is a novel potassium-competitive acid blocker (P-CAB), used for the treatment of acid related disorders - Gastroesophageal Reflux Disease (GERD). Torrent will market Vonoprazan under its own trademark, Kabvie. 

Torrent Pharmaceuticals is flagship company of the Torrent group, a leader in cardiovascular and central nervous system segments. It also has presence in gastro-intestinal, diabetology, anti-infective and pain management segments.


Torrent Pharma Share Price

4093.15 65.55 (1.63%)
09-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1717.35
Dr. Reddys Lab 1212.35
Cipla 1224.25
Zydus Lifesciences 902.15
Lupin 2296.15
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×